Evaluation of Accelerator Mass Spectrometry in a Human Mass Balance and Pharmacokinetic Study–Experience with14C-labeled (R)-6-[Amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a Farnesyl Transferase Inhibitor
- 1 July 2002
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (7) , 823-830
- https://doi.org/10.1124/dmd.30.7.823
Abstract
Accelerator mass spectrometry (AMS) has been used in a human mass balance and metabolism study to analyze samples taken from four healthy male adult subjects administered nanoCurie doses of the farnesyl transferase inhibitor 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone ([14C]R115777). Plasma, urine, and feces samples were collected at fixed timepoints after oral administration of 50 mg [14C]R115777 (25.4 Bq/mg or 687 pCi/mg i.e., equivalent to 76.257 × 103 dpm) per subject. AMS analysis showed that drug-related 14C was present in the plasma samples with Cmax values ranging from 1.6055 to 2.9074 dpm/ml (1.0525–1.9047 μg/ml) attmax = 2 to 3 h. TheCmax values for acetonitrile extracts of plasma samples ranged from 0.3724 to 0.7490 dpm/ml in the four male subjects. Drug-related 14C was eliminated from the body both in the urine and the feces, with a mean total recovery of 79.8 ± 12.9% in the feces and 13.7 ± 6.2% in the urine. The majority of drug-related radioactivity in urine and feces was excreted within the first 48 h. High-performance liquid chromatography (HPLC)-AMS profiles were generated from radioactive parent drug plus metabolites from pooled diluted urine, plasma, and methanolic feces extracts and matched to retention times of synthetic reference substances, postulated as metabolites. All HPLC separations used no more than 5 dpm injected on-column. The radioactive metabolite profiles obtained compared well with those obtained using liquid chromatography/tandem mass spectometry. This study demonstrates the use of AMS in a human phase I study in which the administered radioactive dose was at least 1000-fold lower than that used for conventional radioactive studies.Keywords
This publication has 18 references indexed in Scilit:
- A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extractsJournal of Pharmaceutical and Biomedical Analysis, 2000
- Pushing the accelerator – speeding up drug research with accelerator mass spectrometryNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms, 2000
- Accelerator Mass Spectrometry in Pharmaceutical Research and Development A New Ultrasensitive Analytical Method for Isotope MeasurementCurrent Drug Metabolism, 2000
- A Mass Balance Study to Evaluate the Biotransformation and Excretion of [14C]‐Triamcinolone Acetonide following Oral AdministrationThe Journal of Clinical Pharmacology, 2000
- Accelerator mass spectrometry and its applicationsReports on Progress in Physics, 1999
- Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atomRapid Communications in Mass Spectrometry, 1999
- A preliminary evaluation of accelerator mass spectrometry in the biomedical fieldJournal of Pharmaceutical and Biomedical Analysis, 1997
- Biomedical accelerator mass spectrometryInternational Journal of Mass Spectrometry and Ion Processes, 1995
- A Regulatory and Industrial Perspective of the Use of Carbon-14 and Tritium Isotopes in Human ADME StudiesPharmaceutical Research, 1994
- Radiocarbon Dating Using Electrostatic Accelerators: Negative Ions Provide the KeyScience, 1977